72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Autor: Boffito, Marta, Clayden, Polly, Peto, Tim, Pozniak, Anton, Taylor, Graham, Kambugu, Andrew, Ayabo, Tabitha, Kitaka, Sabrina Bakeera, Byakika-Kibwika, Pauline, Kiiza, Daniel, Kyohairwe, Isabella, Laker, Eva, Luswata, Andrew, Magoola, Johnson, Mayanja, Hamza, Najujuma, Flavia Vivian, Nakijoba, Ritah, Namuddu, Diana, Namuli, Teopista, Ntuyo, Peter, Onzia, Annet, Sempijja, Emmanuel, Tabwenda, Jovia, William, Baluku, Abrahams, Nina, Magano, Phakamani, Delport, Carmen, Hlwaya, Linda, Mehta, Ushma, Molitsane, Dineo, Odayar, Jasantha, Tambula, Sivuyile, Tyam, Mbuviswa, Venfolo, Olga, Allerton, Joanna, Nkonyana, Thozama, Mqaba, Sibongile, Else, Laura, Potter, Steve, Neary, Anne, Malaba, Thokozile R, Nakatudde, Irene, Kintu, Kenneth, Colbers, Angela, Chen, Tao, Reynolds, Helen, Read, Lucy, Read, Jim, Stemmet, Lee-Ann, Mrubata, Megan, Byrne, Kelly, Seden, Kay, Twimukye, Adelline, Theunissen, Helene, Hodel, Eva Maria, Chiong, Justin, Hu, Nai-Chung, Burger, David, Wang, Duolao, Byamugisha, Josaphat, Alhassan, Yussif, Bokako, Sharon, Waitt, Catriona, Taegtmeyer, Miriam, Orrell, Catherine, Lamorde, Mohammed, Myer, Landon, Khoo, Saye ^*

Publikováno v: In The Lancet HIV August 2022 9(8):e534-e543